Elevation Oncology Stock Today
| ELEV Stock | USD 0.54 0.05 9.19% |
PerformanceWeak
| Odds Of DistressVery High
|
Elevation Oncology is selling for under 0.53579998 as of the 25th of February 2025; that is 9.19 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.54. Elevation Oncology has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 27th of November 2024 and ending today, the 25th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of June 2021 | Category Healthcare | Classification Health Care |
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. The company has 59.12 M outstanding shares of which 8.77 M shares are currently shorted by private and institutional investors with about 2.0 trading days to cover. More on Elevation Oncology
Moving against Elevation Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Elevation Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsElevation Oncology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Elevation Oncology's financial leverage. It provides some insight into what part of Elevation Oncology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Elevation Oncology (ELEV) is traded on NASDAQ Exchange in USA. It is located in 101 Federal Street, Boston, MA, United States, 02110 and employs 29 people. Elevation Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.88 M. Elevation Oncology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 59.12 M outstanding shares of which 8.77 M shares are currently shorted by private and institutional investors with about 2.0 trading days to cover.
Elevation Oncology currently holds about 122.54 M in cash with (56.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Elevation Oncology Probability Of Bankruptcy
Ownership AllocationElevation Oncology holds a total of 59.12 Million outstanding shares. The majority of Elevation Oncology outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Elevation Oncology to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Elevation Oncology. Please pay attention to any change in the institutional holdings of Elevation Oncology as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Elevation Ownership Details
Elevation Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Orbimed Advisors, Llc | 2024-09-30 | 941.3 K | |
| Millennium Management Llc | 2024-12-31 | 815.9 K | |
| Ikarian Capital, Llc | 2024-12-31 | 690 K | |
| Ameriprise Financial Inc | 2024-12-31 | 444 K | |
| Northern Trust Corp | 2024-12-31 | 432.6 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 420.4 K | |
| Schonfeld Strategic Advisors Llc | 2024-12-31 | 333.3 K | |
| Two Sigma Investments Llc | 2024-12-31 | 215.9 K | |
| Stonepine Capital Management Llc | 2024-12-31 | 200 K | |
| Tang Capital Management Llc | 2024-12-31 | 4.8 M | |
| Farallon Capital Management, L.l.c. | 2024-12-31 | 3.5 M |
Elevation Oncology Historical Income Statement
Elevation Stock Against Markets
Elevation Oncology Corporate Management
| Joseph Ferra | Chief Officer | Profile | |
| Valerie MD | Chief Officer | Profile | |
| RPh PharmD | President, Founder | Profile | |
| Ryan Bloomer | Head CMC | Profile | |
| Biren Shah | Senior Development | Profile | |
| Brian Sullivan | VP Devel | Profile | |
| Candice Masse | Senior Relations | Profile |
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.